Pericardial effusion coincident with sirolimus therapy: A review of wyeth's safety database

Transplantation

Volumn 85, Issue 4, 2008, Pages 645-647

  Steele, George H ^a   Adamkovic, Anthony B ^a   Demopoulos, Laura A ^a   Rothrock, Linda C ^a   Caulfield, Maureen E ^a   Blum, Michael D ^a   Schubert, Charles M ^a   Hembekides, Dany D ^a   Singh, Ajay B ^a  

^a PFIZER INC   (United States)

Author keywords

Adverse reaction; Cardiac tamponade; Pericardial effusion; Sirolimus; Transplantation

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ARTICLE; FACTUAL DATABASE; FOLLOW UP; HEART TAMPONADE; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGY; PERICARDIAL EFFUSION;

AZATHIOPRINE; CARDIAC TAMPONADE; DATABASES, FACTUAL; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PERICARDIAL EFFUSION; SIROLIMUS;

EID: 44449115763     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181636061     Document Type: Review

References (15)

1. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. Circulation 2004; 110: 2694.
2. Kahan BD, for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study. Lancet 2000; 356: 194.
3. MacDonald AS, for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/ cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
4. CIOMS Current Challenges in Pharmacovigilance: Pragmatic Approaches. Report of CIOMS Working Group V. Geneva: Council for International Organizations of Medical Sciences; 2001.
5. Sagrista-Sauleda J, Merce J, Permanyer-Miralda G, Soler-Soler J. Clinical clues to the causes of large pericardial effusions. Am J Med 2000; 109: 95.
6. Shirwany A, D'Cruz IA, Munir A. Very large pericardial effusion attributable to minoxidil: Resolution without drainage of fluid. Echocardiography 2002; 19: 513.
7. Hauptman PJ, Couper GS, Aranki SF, et al. Pericardial effusions after cardiac transplantation. J Am Coll Cardiol 1994; 23: 1625.
8. Carrier M, Hudon G, Paquet E, et al. Mediastinal and pericardial complications after heart transplantation. Not-so-unusual postoperative problems? Cardiovasc Surg 1994; 2: 395.
9. Quin JA, Tauriainen MP, Huber LM, et al. Predictors of pericardial effusion after orthotopic heart transplantation. J Thorac Cardiovasc Surg 2002; 124: 979.
10. Zucker MJ, Baran DA, Arroyo LH, et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: A one-year follow-up analysis. Transplant Proc 2005; 37: 2231.
11. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6: 986.
12. Sever MS, Steinmuller DR, Hayes JM, et al. Pericarditis following renal transplantation. Transplantation 1991; 51: 1229.
13. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-related complications. Transplantation 2004; 78: 264.
14. Truong U, Moon-Grady AJ, Butani L. Cardiac tamponade in a pediatric renal transplant recipient on sirolimus therapy. Pediatr Transplant 2005; 9: 541.
15. Huber S. Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impeded lymphangiogenesis. Kidney Int 2007; 71: 771.